Bacillibactin
Based on 1 Customer Validation
Bacillibactin (Corynebactin) is a cyclic tricatecholate siderophore. Bacillibactin’s primary function is to facilitate bacterial iron acquisition by chelating iron ions (Fe3+) from the environment, thereby aiding bacterial survival under iron-limited conditions. Bacillibactin exhibits direct antimicrobial activity, such as inhibition of the growth of the producing bacteria Pseudomonas aeruginosa and Aeromonas veronae, as well as plant pathogens such as Pseudomonas syringae.Bacillibactin can be used in antibacterial and antifungal research.
For research use only. We do not sell to patients.
- Purity : 98.1%
- CAS No.: 95536-41-7
- Formula: C39H42N6O18
- Molecular Weight:882.78
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
In Vitro
Bacillibactin demonstrates strong inhibitory activity against Pseudomonas aeruginosa and Aeromonas veronii[1].
Bacillibactin significantly inhibites the growth of P. syringae pv. tomato, Pst under iron starvation conditions and inhibits the growth of a wider range of fungal pathogens (Such as Fusarium, Rhizoctonia, Aspergillus, Verticillium, etc.)[3].
Bacillibactin (10 μM) shows an inhibition rate of less than 20% against two human cancer cell lines (HepG2 liver cancer cells and MCF7 breast cancer cells), indicating that it does not exhibit significant in vitro anti-tumor activity[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 95536-41-7
-
Appearance Solid
-
Molecular Weight 882.78
-
Formula C39H42N6O18
-
SMILES
O=C(C1=C(C(O)=CC=C1)O)NCC(N[C@H]2[C@H](OC([C@H]([C@H](OC([C@H]([C@H](OC2=O)C)NC(CNC(C3=C(C(O)=CC=C3)O)=O)=O)=O)C)NC(CNC(C4=C(C(O)=CC=C4)O)=O)=O)=O)C)=O
-
Synonyms
Corynebactin
-
Structure Classification
-
Initial Source
Brevibacterium sp.
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Bacterial live/dead nucleic-acid viability staining
The LIVE/DEAD bacterial viability staining method is based on differential permeability of nucleic-acid-binding fluorescent dyes, most commonly SYTO 9 and propidium iodide (PI), which enables discrimination of bacterial populations with intact versus compromised cytoplasmic membranes. SYTO 9 penetrates both intact and damaged bacterial membranes and binds nucleic acids to produce green fluorescence, whereas propidium iodide penetrates only cells with compromised membranes and fluoresces red while also reducing SYTO 9 signal through competitive binding and fluorescence interactions. The resulting fluorescence pattern is interpreted as a proxy for membrane integrity, which is widely used as an indicator of bacterial viability in microscopy, flow cytometry, and spectroscopic platforms. However, mechanistic studies show that SYTO 9 and PI interactions involve displacement and fluorescence resonance energy transfer effects, which can influence signal interpretation depending on dye ratios a
Purity & Documentation
-
Data Sheet (271 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Prazdnova E, et al. Bacillibactin, a Potential Bacillus-Based Antibacterial Non-Ribosomal Peptide: In Silico Studies for Targeting Common Fish Pathogens. Int J Mol Sci. 2025 Jun 17;26(12):5811. [Content Brief]
[2]. Pi H, Helmann JD. Genome-Wide Characterization of the Fur Regulatory Network Reveals a Link between Catechol Degradation and Bacillibactin Metabolism in Bacillus subtilis. mBio. 2018 Oct 30;9(5):e01451-18. [Content Brief]
[3]. Dimopoulou A, et al. Direct Antibiotic Activity of Bacillibactin Broadens the Biocontrol Range of Bacillus amyloliquefaciens MBI600. mSphere. 2021 Aug 25;6(4):e0037621. [Content Brief]
[4]. Zhou M, et al. Bacillibactin and Bacillomycin Analogues with Cytotoxicities against Human Cancer Cell Lines from Marine Bacillus sp. PKU-MA00093 and PKU-MA00092. Mar Drugs. 2018 Jan 10;16(1):22. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)